These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21547538)

  • 1. The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor.
    Baker JG; Proudman RG; Tate CG
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jul; 384(1):71-91. PubMed ID: 21547538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.
    Baker JG
    PLoS One; 2010 Nov; 5(11):e15487. PubMed ID: 21152092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
    Baker JG; Hall IP; Hill SJ
    Br J Pharmacol; 2002 Oct; 137(3):400-8. PubMed ID: 12237261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.
    Baker JG; Hall IP; Hill SJ
    Mol Pharmacol; 2003 Jun; 63(6):1312-21. PubMed ID: 12761341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A monoclonal antibody raised against a thermo-stabilised β
    Soave M; Cseke G; Hutchings CJ; Brown AJH; Woolard J; Hill SJ
    Biochem Pharmacol; 2018 Jan; 147():38-54. PubMed ID: 29102678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.
    Baker JG; Proudman RG; Hill SJ
    Mol Pharmacol; 2014 May; 85(5):811-29. PubMed ID: 24608857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site of action of beta-ligands at the human beta1-adrenoceptor.
    Baker JG
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1163-71. PubMed ID: 15716385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.
    Baker JG; Proudman RG; Hill SJ
    PLoS One; 2013; 8(11):e77582. PubMed ID: 24250787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation.
    Gherbi K; May LT; Baker JG; Briddon SJ; Hill SJ
    FASEB J; 2015 Jul; 29(7):2859-71. PubMed ID: 25837585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.
    Warne T; Moukhametzianov R; Baker JG; Nehmé R; Edwards PC; Leslie AG; Schertler GF; Tate CG
    Nature; 2011 Jan; 469(7329):241-4. PubMed ID: 21228877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of the secondary, low-affinity β1 -adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP.
    Gherbi K; Briddon SJ; Hill SJ
    Br J Pharmacol; 2014 Dec; 171(23):5431-45. PubMed ID: 25052258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist.
    Baker JG; Hall IP; Hill SJ
    Br J Pharmacol; 2003 May; 139(2):232-42. PubMed ID: 12770928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
    Baker JG
    Br J Pharmacol; 2010 Jul; 160(5):1048-61. PubMed ID: 20590599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartate138 is required for the high-affinity ligand binding site but not for the low-affinity binding site of the beta1-adrenoceptor.
    Joseph SS; Colledge WH; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Sep; 370(3):223-6. PubMed ID: 15322738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
    Baker JG
    Br J Pharmacol; 2005 Feb; 144(3):317-22. PubMed ID: 15655528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human beta1-adrenoceptor.
    Baker JG; Proudman RG; Hawley NC; Fischer PM; Hill SJ
    Mol Pharmacol; 2008 Nov; 74(5):1246-60. PubMed ID: 18687809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering an ultra-thermostable β(1)-adrenoceptor.
    Miller JL; Tate CG
    J Mol Biol; 2011 Oct; 413(3):628-38. PubMed ID: 21907721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryloxypropanolamine and catecholamine ligand interactions with the beta(1)-adrenergic receptor: evidence for interaction with distinct conformations of beta(1)-adrenergic receptors.
    Konkar AA; Zhu Z; Granneman JG
    J Pharmacol Exp Ther; 2000 Sep; 294(3):923-32. PubMed ID: 10945842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutively active mutants of the beta1-adrenergic receptor.
    Lattion A; Abuin L; Nenniger-Tosato M; Cotecchia S
    FEBS Lett; 1999 Sep; 457(3):302-6. PubMed ID: 10471797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands.
    Baker JG; Middleton R; Adams L; May LT; Briddon SJ; Kellam B; Hill SJ
    Br J Pharmacol; 2010 Feb; 159(4):772-86. PubMed ID: 20105183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.